Xia et al. (2021) demonstrated that inactivating GNA13 by targeting its palmitoylation enhanced the sensitivity of GCB-DLBCL to the BCL2 inhibitor, which further showed the clinical significance of the gene. Research into the role of CIITA in lymphoma has focused on gray zone lymphoma (GZL) (Eberle et al., 2011). A 2019 study revealed that cases of GZL with LBCL-like morphology had more PD-L1/PD-L2 or CIITA rearrangements than cHL-like cases, which presented genetic immune escape features (Sarkozy et al., 2019). The gene discussed is CIITA; the disease is lymphoma.